Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
Your search for dabigatran returned 42 results
New recommendations have been developed for the optimum management of atrial fibrillation.
Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.
For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.
For patients undergoing lower-extremity arthroplasty, a mobile compression device is noninferior to pharmacological protocols for the prevention of venous thromboembolism.
Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.
Almost all the various treatment options for acute venous thromboembolism are equally safe and effective, according to a new study.
For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality.
Patients taking the new generation of oral anticoagulants appear to have a higher risk of gastrointestinal bleeding compared with standard care.
Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin